These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 11106549)
1. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Kupferman ME; Fini ME; Muller WJ; Weber R; Cheng Y; Muschel RJ Am J Pathol; 2000 Dec; 157(6):1777-83. PubMed ID: 11106549 [TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589 [TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086 [TBL] [Abstract][Full Text] [Related]
4. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Ha HY; Moon HB; Nam MS; Lee JW; Ryoo ZY; Lee TH; Lee KK; So BJ; Sato H; Seiki M; Yu DY Cancer Res; 2001 Feb; 61(3):984-90. PubMed ID: 11221894 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of TIMP-1 under the MMP-9 promoter interferes with wound healing in transgenic mice. Salonurmi T; Parikka M; Kontusaari S; Pirilä E; Munaut C; Salo T; Tryggvason K Cell Tissue Res; 2004 Jan; 315(1):27-37. PubMed ID: 14569458 [TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729 [TBL] [Abstract][Full Text] [Related]
8. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046 [TBL] [Abstract][Full Text] [Related]
9. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Witty JP; Lempka T; Coffey RJ; Matrisian LM Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342 [TBL] [Abstract][Full Text] [Related]
15. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685 [TBL] [Abstract][Full Text] [Related]
16. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070 [TBL] [Abstract][Full Text] [Related]
17. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Zhang H; Stephens LC; Kumar R Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771 [TBL] [Abstract][Full Text] [Related]
18. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408 [TBL] [Abstract][Full Text] [Related]
19. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Szabova L; Chrysovergis K; Yamada SS; Holmbeck K Oncogene; 2008 May; 27(23):3274-81. PubMed ID: 18071307 [TBL] [Abstract][Full Text] [Related]
20. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]